## 10/535376

### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 3 June 2004 (03.06.2004)

**PCT** 

# (10) International Publication Number WO 2004/046892 A2

(51) International Patent Classification7:

\_\_\_\_

G06F

(21) International Application Number:

PCT/US2003/037214

(22) International Filing Date:

20 November 2003 (20.11.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/427,771

20 November 2002 (20.11.2002) US

- (71) Applicant (for all designated States except US): AVEN-TIS PHARMACEUTICALS INC. [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, NJ 08807 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): POWERS, Joseph [US/US]; 16E Lincoln Place, New Brunswick, NJ 08902 (US). REHM, William [US/US]; 67 Haytown Road, Lebanon, NJ 08833 (US). LETOURNEAU, Carla [CA/CA]; 46 av Chester, Pointe-Claire, Québec H9R 4J1 (CA). PENDLETON, Danny [CA/CA]; 24 Glastonbury Dr., Moncton, New Brunswick E1A 8K3 (CA). LAHAYE, Stephen [CA/CA]; 4583 Bath Road, Amherstview, Ontario K7N 1A8 (CA).


- (74) Agent: SIMPSON, Mark; Synnestvedt & Lechner LLP, 2600 Aramark Tower, 1101 Market Street, Philadelphia, PA 19107-2950 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

[Continued on next page]

#### (54) Title: METHOD AND SYSTEM FOR MARKETING A TREATMENT REGIMEN



(57) Abstract: A software program, for use on a computing device such as a Personal Digital Assistant (PDA) device, is provided to a health care provider (HCP). The software program configures the computing device with means for inputting profile information regarding patients and means for comparing the patient profile information against a database containing information regarding one or more drug studies performed on patients having similar medical histories and/or symptoms. The patient information is compared against the database, and, where appropriate, the healthcare provider is made aware that the patient associated with the patient profile could benefit from being prescribed to take the drug or drugs on which the study is based, and/or at a particular dose indicated by the study.

